Escape velocity out of a small base: management describes the business compounding at a rate its own size cannot absorb
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes the company as being at a point where the rate of accumulation is the dominant fact, using multiples of recent past, and treating the company as still small. Let's analyze the transcript. Key points from Chris Anzalone's opening: "We've seen clear progress across our large and balanced pipeline, large because it now includes 12 drug candidates in clinical trials and balanced because it spans in multiple therapeutic areas and includes six partnered programs and six that are wholly owned." That's a count, not a multiple. Later: "we are announcing our 20 in ‘25 program. We plan to have 20 individual drug candidates in clinical trials or in the market in 2025." That's a target, not already banked. He says: "We have increased clarity as to how large we think our pipeline of clinical candidates will be over the next few years" - that's future. He mentions "we expect to report on progress for fazirsiran... in the near term." Not a multiple. He talks about "interim analyses for the SHASTA-2 and MUIR studies... gave us some critical insights" - not a multiple. He says: "we have line of sight on timelines for initial interim clinical results for two of our pulmonary programs." Not a multiple. He says: "we continue to expand our platform into new cell types and have made enough progress to give us line of sight as to when we can discuss one of them publicly. I expect to provide guidance about our next cell type and initial targets by the end of the first half of 2023." Not a multiple. He says: "we have a good idea about how large we think we can grow our pipeline in the near- to mid-term and are announcing our 20 in ‘25 program." That's a target. He says: "We currently have partnerships with five different companies and we expect to receive milestone payments from each over the next 12 months." That's a count, not a multiple. He says: "we recently decided to sell the potential royalties we would receive from Amgen on future olpasiran sales to Royalty Pharma. We received $250 million in cash upfront and up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones." That's a transaction, not a multiple.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| SNOW | Snowflake Inc. | Q3 2022 | 2021-12-01 | A |
SNOW · Q3 2022 → YESThe question is about whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as st...YES Frank Slootman repeatedly frames the current state in terms of multiples of the recent past: product revenue “growing 110% year-on-year” (more than doubling), EMEA “up 174%” and Asia-Pacific “219%”, BUILD Summit registrations “three times last year’s”, Snow Day “ 23,000 registrations”, Data Marketplace “grew 41%”, stable edges “more than 130% annual increase”, Powered By Snowflake partners “growing 137% quarter-on-quarter” and product revenue from them “173% year-on-year”.
DASH · Q3 2023 → YESThe question is whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as still sm...YES The transcript shows management repeatedly framing the business in terms of multiples of its recent past: non-restaurant selection "going from 0 nearly 3 years ago to a multibillion-dollar business that's at scale now growing fast"; grocery GOV "has doubled year-on-year"; international growth "at multiples of what we see around the world"; and new verticals accelerating from the prior quarter.
SYM · Q3 2022 → YESThe question is about whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as st...YES Management repeatedly frames the current state using multiples of recent past activity: backlog more than doubled (from $5.2B to $11.